Nivolumab: beside a new treatment under test
581 studies: a new drug, cell therapy or vaccine is what the study tests. Page 5 of 6. Open to participants first (106), then studies with results posted, then the rest; newest registration first within each.
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT04495296Phase 1/2How we knowReport a problem
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)CompletedNCT04495257Phase 1How we knowReport a problem
- A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT04477343Phase 1How we knowReport a problem
- Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1TerminatedNCT04455503Phase 1/2How we knowReport a problem
- A Study of DF6002 Alone and in Combination With NivolumabCompletedNCT04423029Phase 1How we knowReport a problem
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaCompletedNCT04420975Phase 1How we knowReport a problem
- A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT04396821Phase 1/2How we knowReport a problem
- Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsActive, not recruitingNCT04336241Phase 1How we knowReport a problem
- Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological MalignanciesTerminatedNCT04305249Phase 1How we knowReport a problem
- Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaActive, not recruitingNCT04300244Phase 2How we knowReport a problem
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT04300140Phase 1/2How we knowReport a problem
- Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsCompletedNCT04299880Phase 1How we knowReport a problem
- A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsTerminatedNCT04278144Phase 1/2How we knowReport a problem
- Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersTerminatedNCT04270864Phase 1How we knowReport a problem
- Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentCompletedNCT04263090Phase 1/2How we knowReport a problem
- Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerCompletedNCT04263051Phase 2How we knowReport a problem
- A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Status unknownNCT04250246Phase 2How we knowReport a problem
- GVAX Plus Checkpoint Blockade in NeuroblastomaTerminatedNCT04239040Phase 1How we knowReport a problem
- Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1How we knowReport a problem
- Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell CarcinomaTerminatedNCT04203901Phase 2How we knowReport a problem
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaCompletedNCT04200963Phase 1How we knowReport a problem
- Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung CancerStatus unknownNCT04199559Phase 1/2How we knowReport a problem
- Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionActive, not recruitingNCT04180371Phase 1/2How we knowReport a problem
- Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for MelanomaCompletedNCT04165967Phase 1How we knowReport a problem
- Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsActive, not recruitingNCT04165330Phase 1/2How we knowReport a problem
- Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota TransplantationActive, not recruitingNCT04163289Phase 1How we knowReport a problem
- Study of DF1001 in Patients With Advanced Solid TumorsCompletedNCT04143711Phase 1/2How we knowReport a problem
- Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid TumorsStatus unknownNCT04142931Phase 1How we knowReport a problem
- A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCompletedNCT04132817Phase 1How we knowReport a problem
- PVSRIPO in Combination With Nivolumab in MelanomaWithdrawnNCT04125719Phase 1How we knowReport a problem
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerActive, not recruitingNCT04117087Phase 1How we knowReport a problem
- A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabCompletedNCT04112498Phase 1How we knowReport a problem
- Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsCompletedNCT04084951Phase 1How we knowReport a problem
- Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerActive, not recruitingNCT04080804Phase 2How we knowReport a problem
- SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)Active, not recruitingNCT04079166Phase 2How we knowReport a problem
- A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingNCT04078295Phase 1/2How we knowReport a problem
- Study of ARRY-614 Plus Either Nivolumab or Nivolumab+IpilimumabActive, not recruitingNCT04074967Phase 1/2How we knowReport a problem
- Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLCTerminatedNCT04069936Phase 2How we knowReport a problem
- CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnNCT04060407Phase 1/2How we knowReport a problem
- SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerCompletedNCT04050085Phase 1How we knowReport a problem
- Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04047706Phase 1How we knowReport a problem
- ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)Active, not recruitingNCT04044859Phase 1How we knowReport a problem
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorSuspendedNCT04042116Phase 1/2How we knowReport a problem
- Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaCompletedNCT04040231Phase 1How we knowReport a problem
- NeoVax With Nivolumab in Patients With Ovarian CancerActive, not recruitingNCT04024878Phase 1How we knowReport a problem
- MTG201 Plus Nivolumab in Patients With Relapsed Pleural MesotheliomaStatus unknownNCT04013334Phase 2How we knowReport a problem
- IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMActive, not recruitingNCT04003649Phase 1How we knowReport a problem
- A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal CancerStatus unknownNCT03993626Phase 1/2How we knowReport a problem
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)CompletedNCT03980041Phase 2How we knowReport a problem
- A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid TumorsSuspendedNCT03970382Phase 1How we knowReport a problem
- An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersCompletedNCT03956680Phase 1How we knowReport a problem
- A Study of a Personalized Cancer Vaccine Targeting Shared NeoantigensCompletedNCT03953235Phase 1/2How we knowReport a problem
- Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCTerminatedNCT03952325Phase 2How we knowReport a problem
- PAC-1 for Treatment of Refractory, Metastatic Kidney CancerWithdrawnNCT03927248Phase 1/2How we knowReport a problem
- Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaCompletedNCT03922880Phase 1How we knowReport a problem
- Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell LymphomasWithdrawnNCT03920631Phase 1How we knowReport a problem
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerActive, not recruitingNCT03907852Phase 1/2How we knowReport a problem
- A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck CancerTerminatedNCT03906526Phase 1How we knowReport a problem
- Tinostamustine and Nivolumab in Advanced MelanomaStatus unknownNCT03903458Phase 1How we knowReport a problem
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)CompletedNCT03893695Phase 1/2How we knowReport a problem
- Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGGCompletedNCT03879512Phase 1/2How we knowReport a problem
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedNCT03872947Phase 1How we knowReport a problem
- iSCORE: Immunotherapy Sequencing in COlon and REctal CancerActive, not recruitingNCT03867799Phase 2How we knowReport a problem
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Active, not recruitingNCT03865082Phase 2How we knowReport a problem
- A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerCompletedNCT03850067Phase 1How we knowReport a problem
- Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for LymphomaActive, not recruitingNCT03843294Phase 1How we knowReport a problem
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1How we knowReport a problem
- TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersCompletedNCT03829436Phase 1How we knowReport a problem
- CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerCompletedNCT03829111Phase 1How we knowReport a problem
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1How we knowReport a problem
- Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid TumorsStatus unknownNCT03792724Phase 1/2How we knowReport a problem
- Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.Status unknownNCT03784040Phase 1How we knowReport a problem
- Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)Active, not recruitingNCT03772899Phase 1How we knowReport a problem
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaActive, not recruitingNCT03769155Phase 1How we knowReport a problem
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active, not recruitingNCT03767348Phase 2How we knowReport a problem
- IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsCompletedNCT03758781Phase 1How we knowReport a problem
- An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid TumorsCompletedNCT03745807Phase 1How we knowReport a problem
- Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsCompletedNCT03730337Phase 1How we knowReport a problem
- Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1TerminatedNCT03721679Phase 1/2How we knowReport a problem
- Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic NivolumabActive, not recruitingNCT03707808Phase 1/2How we knowReport a problem
- Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of GlioblastomaTerminatedNCT03707457Phase 1How we knowReport a problem
- VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruitingNCT03690986Phase 1How we knowReport a problem
- COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.CompletedNCT03667716Phase 1How we knowReport a problem
- An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03661632Phase 1How we knowReport a problem
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCTerminatedNCT03655613Phase 1/2How we knowReport a problem
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerActive, not recruitingNCT03655002Phase 1How we knowReport a problem
- Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerCompletedNCT03647839Phase 2How we knowReport a problem
- Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsActive, not recruitingNCT03647163Phase 1/2How we knowReport a problem
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedNCT03645928Phase 2How we knowReport a problem
- A Study of a Personalized Neoantigen Cancer VaccineCompletedNCT03639714Phase 1/2How we knowReport a problem
- TIL and Anti-PD1 in Metastatic MelanomaActive, not recruitingNCT03638375Phase 1/2How we knowReport a problem
- Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineCompletedNCT03633110Phase 1/2How we knowReport a problem
- Nivolumab and Relatlimab in Treating Participants With Advanced ChordomaCompletedNCT03623854Phase 2How we knowReport a problem
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 2How we knowReport a problem
- Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaCompletedNCT03605719Phase 1How we knowReport a problem
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedNCT03597282Phase 1How we knowReport a problem
- NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyActive, not recruitingNCT03589339Phase 1How we knowReport a problem
- Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerWithdrawnNCT03576963Phase 1/2How we knowReport a problem
- GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade GliomasCompletedNCT03576612Phase 1How we knowReport a problem
- Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity StudyCompletedNCT03575598Early Phase 1How we knowReport a problem